Floatz logo

Sabatolimab

Bone Marrow Diseases

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Bone Marrow Diseases cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Tazobactam
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Piperacillin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Vancomycin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2B

View all 27 →

Same molecule, other indications

Sabatolimab is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
42 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
37 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →